The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Dose modifications of talquetamab to manage AEs in patients with multiple myeloma
Amrita Krishnan, MD, City of Hope, Duarte, CA, discusses strategies for managing treatment-related adverse events (AEs) associated with talquetamab treatment in patients with multiple myeloma (MM). Dose modifications are often successfully used to reduce AEs but should be carefully calculated to ensure treatment effects are optimized. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So one of the updates going to be presented today at the meeting, is in regards to talquetamab and dose modifications, suggesting that, you know, certainly the majority of patients end up with dose modifications because of some of the AEs. But the encouraging thing is, with those dose modifications, that patients can maintain responses and the further treatment-emergent AEs seem to come down...
So one of the updates going to be presented today at the meeting, is in regards to talquetamab and dose modifications, suggesting that, you know, certainly the majority of patients end up with dose modifications because of some of the AEs. But the encouraging thing is, with those dose modifications, that patients can maintain responses and the further treatment-emergent AEs seem to come down. So again, just suggesting management strategies, now that we do have taquetamab available to us commercially, in regards to optimizing response durations for these patients.
Read more...
Disclosures
Stock Options/Ownership-Public Company: Bristol-Myers Squibb Company
Speakers Bureau: Amgen Inc, Bristol-Myers Squibb Company, Takeda Pharmaceuticals USA Inc
Contracted Research: Janssen Biotech
Consultancy: Adaptive Biotechnologies Corporation, Bristol-Myers Squibb Company, GlaxoSmithKline, Regeneron Pharmaceuticals Inc, Sanofi Genzyme
Advisory Committee: Sutro Biopharma
